Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Rosu – page 4

227 clinical trials in Rosu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Rosu at a glance
227
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

227 trials in Rosu

Open in trial search

Schizophrenia

Recruiting

Efficacy and safety of roluperidone versus drug combination in adults with schizophrenia with negative symptoms

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Aripiprazole
  • Sponsor:Minerva Neurosciences Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Innocare Pharma Inc.

Schizophrenia+1

Recruiting

Long‑Term Safety and Tolerability of KarXT in Adolescents with Schizophrenia and of KarXT + KarX‑EC in Children and Adolescents with Autism‑Related Irritability

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide
  • Sponsor:Quetzal Therapeutics LLC

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effectiveness and safety of clemizole hydrochloride as an additional treatment for patients with Lennox-Gastaut syndrome

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years
  • Substances:Clemizole Hydrochloride
  • Sponsor:Epygenix Therapeutics Inc.

Schizophrenia

Recruiting

A study to evaluate the efficacy and safety of trospium chloride and xanomeline tartrate for the treatment of schizophrenia in adolescents aged 13 to 17 years

Investigational
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Rosu

What the registry says about research in the country

01 Cardiovascular Disease – Atrial Fibrillation

Research in Rosu is centered on a common heart rhythm disorder that raises the chance of serious vascular events.

  • Evaluation of REGN7508 compared with standard anticoagulant therapy
  • Combined REGN7508 and REGN9933 versus placebo
  • Risk assessment of clinically relevant bleeding
  • Stroke and systemic embolism prevention for patients unsuitable for oral anticoagulation

The trials aim to expand treatment choices and lower the incidence of stroke and embolic complications in atrial fibrillation.

02 Anticoagulation Safety in Atrial Fibrillation

Ongoing studies examine how to protect patients from ischemic stroke while reducing the likelihood of major bleeding events.

  • Comparison of bleeding risk between experimental agents and apixaban
  • Evaluation of major bleeding outcomes with dual‑target therapy
  • Analysis of stroke prevention effectiveness in high‑risk cohorts
  • Safety profiling for participants unable to use conventional oral anticoagulants

Findings are expected to inform safer anticoagulation strategies for individuals living with atrial fibrillation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.